A/H1N1 Immunogenicity and Safety in Adults
An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older
Sponsor: Alachua Government Services, Inc.
Listed as NCT00959465, this PHASE1/PHASE2 trial focuses on Influenza and Pandemic Influenza and remains completed. Sponsored by Alachua Government Services, Inc., it has been updated 6 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Aug 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alachua Government Services, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .